Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis

BACKGROUND: Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation-positive metastatic castration-resistant PCa (mCRPC) patients following prior treatment with abiraterone, enzalutamide or docet...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazekas, Tamás, Széles, Ádám D., Teutsch, Brigitta, Csizmarik, Anita, Vékony, Bálint, Váradi, Alex, Kói, Tamás, Lang, Zsolt, Ács, Nándor, Kopa, Zsolt, Hegyi, Péter, Hadaschik, Boris, Grünwald, Viktor, Nyirády, Péter, Szarvas, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638083/
https://www.ncbi.nlm.nih.gov/pubmed/36509931
http://dx.doi.org/10.1038/s41391-022-00626-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638083/
https://www.ncbi.nlm.nih.gov/pubmed/36509931
http://dx.doi.org/10.1038/s41391-022-00626-2

Ejemplares similares